U.S. Subsidiary Change of Name

Hemogenyx Pharmaceuticals plc is pleased to announce that its U.S. subsidiary will be renamed Hemogenyx Pharmaceuticals LLC in order to align the Company’s names across entities and countries, and should always be referred to as Hemogenyx Pharmaceuticals instead of Hemogenyx by itself. The company will continue to conduct preclinical and clinical stage research and development activities to develop its own products and therapies, including therapies and treatments for blood and autoimmune diseases and viral infections. Hemogenyx Pharmaceuticals LLC will remain located at its state-of-the-art research facility in New York City.

Enquiries:

Hemogenyx Pharmaceuticals plc	hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries	Tel: +1 (323) 646-3249
Lowell Goodman	lowell@corbomitecomms.com

View All